<DOC>
	<DOCNO>NCT00635076</DOCNO>
	<brief_summary>The purpose study evaluate long-term ( 6-month ) efficacy , safety , tolerability alprazolam XR adolescents panic disorder .</brief_summary>
	<brief_title>A Study Assess Long-Term Use Alprazolam Extended Release ( XL ) Treatment Adolescents With Panic Disorder</brief_title>
	<detailed_description>Due recruitment difficulty adolescent population , clinical program alprazolam XR cancel study terminate 1 September 2004 . There safety concern lead decision .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Panic Disorder</mesh_term>
	<mesh_term>Alprazolam</mesh_term>
	<criteria>A primary Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision diagnosis panic disorder without agoraphobia base MiniInternational Neuropsychiatric Interview Children Adolescents Subjects average 1 ) least one 4symptom panic attack per week last 4 week screen ; 2 ) least one 4symptom panic attack per week last 4 week baseline ; 3 ) least one 4symptom panic attack 7 day prior baseline To enter Study A6131007 , subject must complete Study A6131002 , acceptable tolerability study drug , clinical judgment investigator , could benefit continued study treatment . Subjects must continue meet exclusion criterion enumerate Acute Efficacy Study ( Protocol A6131002 ) follow exception : Subjects allow undergo cognitivebehavioral panicspecific therapy psychotherapy ( e.g. , supportive and/or family therapy ) expect study period study .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>